UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark One)

|X|   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF 1934

                                          For the quarterly period ended 3/31/01

|_|   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF 1934

      (No Fee Required)

                            For the transition period from _________ to ________

                                                  Commission file number 0-27123

                             MEDIQUIK SERVICES, INC.
      ---------------------------------------------------------------------
                 (Name of small business issuer in its charter)

          Delaware                                        74-2876711
------------------------------              ------------------------------------
State or other jurisdiction of              (I.R.S. Employer Identification No.)
incorporation or organization)

4299 San Felipe, Suite 300, Houston, Texas       77027
--------------------------------------------------------------------------------
(Address of principal executive offices)       (Zip Code)

                                 (832) 200-7000
--------------------------------------------------------------------------------
                           (Issuer's telephone number)

--------------------------------------------------------------------------------
             (Former address :

      Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes |X| No |_|

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

      Check whether the registrant filed all documents and reports required to
be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution
of securities under a plan confirmed by a court. Yes |_| No |_|


                                       1
<PAGE>

--------------------------------------------------------------------------------
                      APPLICABLE ONLY TO CORPORATE ISSUERS:

      State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:

13,504,096 shares of the Company's Common Stock issued and outstanding at March
31, 2001.
--------------------------------------------------------------------------------

      Transitional Small Business Disclosure Format (Check one): Yes |_|; No |X|


                                       2
<PAGE>

                                                                            Page

PART I.  FINANCIAL INFORMATION                                                3

ITEM 1   FINANCIAL STATEMENTS                                                 3

         Consolidated Balance Sheets
           March 31, 2001 (Unaudited) and December 31, 2000                   4

         Consolidated Statements of Operations (Unaudited)
           Three Months Ended March 31, 2001 and 2000                         5

         Consolidated Statements of Cash Flows (Unaudited)
           Three Months Ended March 31, 2001 and 2000                         6

         Notes to Consolidated Financial Statements                           7

ITEM 2   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITION AND RESULTS OF OPERATIONS                                  8

PART II. OTHER INFORMATION                                                   13

ITEM 6.  EXHIBITS AND REPORT ON FORM 8-K                                     13

      A.    Exhibits

      B.    Reports on Form 8-K


                                       3
<PAGE>

PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

MEDIQUIK SERVICES, INC.

CONSOLIDATED BALANCE SHEETS

--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                        March 31,         December 31,
ASSETS                                                                                    2001               2000
                                                                                       (Unaudited)
<S>                                                                                   <C>               <C>
CURRENT ASSETS:
  Cash and cash equivalents                                                           $     11,970      $     18,649
  Accounts receivable, net of allowance of $394,242 and $351,794, respectively             392,424           290,332
  Inventory                                                                                 51,367            55,963
                                                                                      ------------      ------------

      Total current assets                                                                 455,761           364,944

PROPERTY AND EQUIPMENT:
  Office equipment                                                                         131,773           131,497
  Less accumulated depreciation                                                            (24,958)          (20,141)
                                                                                      ------------      ------------

      Total property and equipment                                                         106,815           111,356

INVESTMENTS                                                                              1,303,782         1,303,782

OTHER ASSETS, Net                                                                          424,593           349,382
                                                                                      ------------      ------------

TOTAL                                                                                 $  2,290,951      $  2,129,464
                                                                                      ============      ============

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                                                                    $  1,098,190      $    914,074
  Accrued expenses                                                                         177,752           204,521
  Notes payable and subordinated debentures                                                500,000                --
                                                                                      ------------      ------------

      Total current liabilities                                                          1,775,942         1,118,595

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY:
  Series A preferred stock - $.001 par value 1,000,000 shares authorized,
    513,266 issued and outstanding ($20,530,640 involuntary liquidation preference)            513               513
  Common stock - $.001 par value 50,000,000 shares authorized;
    13,504,096 shares issued and outstanding at March 31, 2001 and
    December 31, 2000                                                                       13,504            13,504
  Additional paid-in capital                                                            16,036,447        16,036,447
  Accumulated deficit                                                                  (15,535,455)      (15,039,595)
                                                                                      ------------      ------------

      Total stockholders' equity                                                           515,009         1,010,869
                                                                                      ------------      ------------

TOTAL                                                                                 $  2,290,951      $  2,129,464
                                                                                      ============      ============
</TABLE>

See accompanying notes to consolidated financial statements (unaudited)

--------------------------------------------------------------------------------


                                       4
<PAGE>

MEDIQUIK SERVICES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

--------------------------------------------------------------------------------
                                                Three Months        Three Months
                                                    ended              ended
                                                  March 31,           March 31,
                                                    2001                2000

SALES                                           $    614,983        $   321,929

COST OF SALES                                        434,650            277,663
                                                ------------        -----------

GROSS PROFIT                                         180,333             44,266

OPERATING EXPENSES:
  Salaries - officers                                 91,768            103,000
  Consulting fees                                     34,967            170,083
  Other                                              547,921            291,351
                                                ------------        -----------

      Total operating expenses                       674,656            564,434
                                                ------------        -----------

LOSS FROM OPERATIONS                                (494,323)          (520,168)

OTHER INCOME (EXPENSE):
  Interest expense                                    (1,537)            (3,119)
                                                ------------        -----------

      Total other (expense) income                     1,537             (3,119)
                                                ------------        -----------

NET LOSS                                        $   (495,860)       $  (523,287)
                                                ============        ===========

BASIC AND DILUTED LOSS PER SHARE                $      (0.04)       $     (0.09)
                                                ============        ===========

BASIC WEIGHTED-AVERAGE NUMBER OF
 COMMON SHARES OUTSTANDING                        13,504,096          6,155,710
                                                ============        ===========

DILUTED WEIGHTED-AVERAGE NUMBER OF
 COMMON SHARES OUTSTANDING                        13,504,096          6,155,710
                                                ============        ===========

See accompanying notes to consolidated financial statements (unaudited)

--------------------------------------------------------------------------------


                                       5
<PAGE>

MEDIQUIK SERVICES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

--------------------------------------------------------------------------------
                                                      Three Months  Three Months
                                                         Ended         Ended
                                                        March 31,     March 31,
                                                          2001          2000

CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss                                             $(495,860)    $(523,287)
  Adjustment for noncash transactions:
    Common stock and warrants issued for services             --       217,749
    Depreciation and amortization                         12,116        15,373
    Provision for losses on accounts receivable           42,448        24,934
  Net changes in assets and liabilities:
    Accounts receivable                                 (144,540)     (187,868)
    Inventory                                              4,596        (7,091)
    Accounts payable                                     184,116       329,116
    Accrued expenses                                     (26,769)     (158,941)
    Other assets                                         (82,510)           --
                                                       ---------     ---------

        Net cash used in operating activities           (506,403)     (290,015)
                                                       ---------     ---------

CASH FLOWS FROM INVESTING ACTIVITIES -
  Capital expenditures                                      (276)         (478)
                                                       ---------     ---------

        Net cash used in investing activities               (276)      (74,601)
                                                       ---------     ---------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from sale of common stock                          --       270,000
  Proceeds from sales of interests in subsidiary              --         8,000
  Proceeds from Ball/MiraQuest transactions              500,000            --
                                                       ---------     ---------

        Net cash provided by financing activities        500,000       278,000
                                                       ---------     ---------

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS      (6,679)      (12,493)

CASH AND CASH EQUIVALENTS, Beginning of period            18,649        47,424
                                                       ---------     ---------

CASH AND CASH EQUIVALENTS, End of period               $  11,970     $  34,931
                                                       =========     =========

SUPPLEMENTAL CASH FLOW DISCLOSURES -
  Interest paid                                        $  12,523     $  26,365

NONCASH TRANSACTIONS:
  Shortterm debt issued for purchase of software       $      --       101,195
  Return to vendor of software package                        --     $  13,500

See accompanying notes to consolidated financial statements (unaudited)

--------------------------------------------------------------------------------


                                       6
<PAGE>

MEDIQUIK SERVICES, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

--------------------------------------------------------------------------------

1. BASIS OF PRESENTATION

      The interim consolidated condensed financial statements and notes thereto
of MediQuik Services, Inc. and its subsidiary (collectively, the "Company" or
"MediQuik") have been prepared by management without audit pursuant to the rules
and regulations of the Securities and Exchange Commission ("SEC"). Accordingly,
the accompanying financial statements reflect all adjustments that, in the
opinion of management, are necessary for a fair presentation of results for the
periods presented. Such adjustments are of a normal recurring nature. Certain
information and notes normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States of
America have been condensed or omitted pursuant to the SEC's rules and
regulations. However, management believes that the disclosures presented herein
are adequate to make the information not misleading. The accompanying condensed
consolidated financial statements and notes should be read in conjunction with
the consolidated financial statements and notes thereto contained in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 2000.

      The preparation of these condensed consolidated financial statements
required the use of estimates and judgments that affect the reported amounts of
assets and liabilities and disclosures of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the periods. Actual results could differ from those estimates.
The results of operations for any interim period are not necessarily indicative
of results for the full year.

2. INVESTMENTS/EQUITY TRANSACTIONS

      In the year 2000, the Company exchanged 7,048,996 shares of its common
stock, 513,266 shares of its Series A preferred stock convertible into
10,265,328 shares of its common stock, and a warrant for 650,000 shares of its
common stock exercisable at $ 0.60 each, for 7,251,600 membership units of
MiraQuest which represented an approximate 17% ownership in the membership units
of MiraQuest. and $2,000,000 in cash. The membership units in MiraQuest were
valued by an independent appraisal at $9,200,000, at September 1, 2000, the
effective date of the transaction, and were recorded at that value. However, in
the fourth quarter of 2000, in accordance with Statements of Financial Account
Standards No. 121 "Accounting for the Impairment of Long-Lived Asses and
Long-Lived Assets to be Disposed of", the Company recognized an impairment of
$7,800,000 in its investment in MiraQuest membership units due to a permanent
decline in value of a major MiraQuest subsidiary. The MiraQuest subsidiary
failed to obtain necessary financing and has ceased its operations. MiraQuest
has determined the fair market value of its investment in the subsidiary was
zero. The Company's impairment was determined based on its pro rata share of the
impairment.


                                       7
<PAGE>

Additionally, the Company reduced its investment in MiraQuest membership units
in the amount of $96,218 for the Company's share of the net loss recognized by
MiraQuest for the three months ended December 31, 2000, the period in which the
Company owned the membership units.

      The Company appointed a committee to study the possibility of
restructuring the MiraQuest transaction in February, 2001. A plan to partially
reverse the original transaction (the "Plan") was approved by both boards on
April 20, 2001. The Plan, as currently stated, would result in (i) the Company's
redemption of all of its currently outstanding preferred shares; (ii) the
Company's return of all of its membership units of MiraQuest; (iii) an
additional cash equity contribution of $500,000 from MiraQuest to the Company;
(iv) the restructuring of the Company's note and warrants to Ball Investors,
LLC, an affiliate of MiraQuest, as well as restructuring the Company's
indebtedness to a third-party vendor; (v) MiraQuest's agreement to sell back to
the Company a number of the Company's common shares for nominal consideration
once another capital partner is found for the Company; and (vi) MiraQuest's
agreement to relinquish control of the Company's board of directors at the next
annual shareholder's meeting. The result of the Plan would be for MiraQuest to
retain approximately 30% equity ownership of the Company. The Company expects
the Plan to be completed by June 30, 2001.

      In the first quarter of 2000, in connection with a private stock offering,
the company received $270,000 and issued 135,000 shares of common stock and
warrants to purchase 270,000 shares of common stock at $2.00 per share. In the
first quarter of 2001, in connection with the Ball Note borrowing of $500,000,
the Company issued warrants to purchase2,680,965 shares of common stock at
$0.373 per share.

Item 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations

Forward Looking Statements

      This management discussion and analysis contains forward-looking
statements as indicated by the use of words like "expects", "believes", and
"anticipates" and other similar words and phrases. Such statements reflect
management's current view of future financial performance based on certain
assumptions, risks, and uncertainties. If any assumptions, risks, uncertainties,
or unanticipated outside factors change or occur, such changes may have a
material impact on actual financial results. The Company is under no obligation
to revise any such forward-looking statements contained herein. Readers are
cautioned to not place undue reliance on any forward-looking statements
contained in this discussion.

Overview

      MediQuik is a healthcare services company specializing in the delivery of
disease management programs to chronically ill patients directly, on behalf of
managed care payors, and through federal and state government programs.


                                       8
<PAGE>

      Our business was organized on April 7, 1998, and began full-time
operations in July 1998 as Old MediQuik. Effective December 31, 1998, Old
MediQuik merged with and into Cash Flow Marketing, Inc., with Cash Flow as the
surviving corporation. Cash Flow changed its name to MediQuik Services, Inc.
immediately following the merger. This transaction has been treated as a capital
transaction in substance rather than a business combination; thus, the
accounting is similar to a reverse acquisition but no goodwill and/or
intangibles have been recorded. As a result Old MediQuik is considered the
accounting acquirer for financial statement purposes. Therefore, our financial
statements for periods prior to January 1, 1999 are the financial statements of
Old MediQuik, not Cash Flow Marketing, Inc.

      Although our initial revenues were derived primarily through product
sales, we have expanded beyond product delivery and have become a full disease
management provider working to improve patient care and reduce costs to managed
care payors. We currently offer managed care agreements based on fee-for-service
and capitated fee arrangements.

      We are currently serving patients with diabetes and intend to provide
disease management programs for other high cost, chronic diseases, such as
asthma, congestive heart failure, and other diseases with large afflicted
patient populations where clinical research indicates that active management
will improve the health condition of the patient and reduce the financial burden
for managed care payors. We are in the process of conducting research regarding
the new disease management programs.

      We offer comprehensive disease monitoring and maintenance solutions by
providing pharmacy and diagnostic products, disease education, adherence review
and reporting, and personal health resources via the U.S. Mail, telephone and
the Internet. We provide a complete line of blood glucose monitoring systems,
testing strips, lancets, swabs, insulin pumps, compliance and wound care
products for diabetes patients. We are adding new products and services, both to
complement existing disease management programs and also to offer a range of
other supplemental or convenience items through our delivery systems. MediQuik
is focused on delivering high quality products and services to chronic disease
patients, whether individually, through government programs, direct to the
employer, or for insurance organizations that bear the primary financial risk
for healthcare treatment. MediQuik also works directly with health maintenance
organizations (HMOs), preferred provider organizations (PPOs), self-insured
companies and other third-party payors (TPAs) in an effort to enhance the
quality of life for chronically ill patients and improve the financial outcomes
for managed care payors. We also provide billing and collection activities on
behalf of the patient to the healthcare plan.

Plan of Operation

      We intend to grow by acquiring additional managed care customers,
increasing our market penetration of the plans we already service, and by
seeking additional strategic partners through acquisitions or merger. At the
same time, we will seek efficiencies of volume, increased customer service
through information technology


                                       9
<PAGE>

implementation, and securing the financial resources to implement purchasing and
delivery cost reductions. We have reduced expenses by a reduction in force and
by salary reductions, and have increased participation in the incentive stock
option plan by including all employees and increasing the amounts of shares
covered.

Liquidity and Capital Resources

      Our principal cash requirements to date have been to fund working capital
in order to support growth of net sales. Because revenue from operations has
been inadequate to completely fund these requirements, we have supplemented our
revenue from operations with proceeds from private offerings of securities,
loans and extensions of credit from vendors in order to meet working capital
requirements, and the MiraQuest transaction. We have instituted cost saving
measures, including a reduction in force and salary reductions. We have
implemented a stock incentive program to align employee and company goals and
reward outstanding performance. We anticipate that as revenue from sales to
managed care plans increases, we will be able to satisfy all of our funding
requirements for operations from such revenue, however, we cannot assure you
that this will be the case. We had an aggregate of $11,970 in cash as of March
31, 2001.

      We had no debt outstanding as of December 31, 2000. We have accrued wages
of approximately $45,000 primarily to directors, officers, and insiders who are
our significant shareholders. We expect to pursue additional equity and debt
financing to meet future working capital requirements.

      In February of 2001, our Board of Directors appointed a Transaction Review
Committee (the "Committee") to study alternative methods of restructuring the
MiraQuest transaction in order to allow us to better seek additional equity and
debt financing. On April 20, 2001, the Boards of Directors of both the Company
and MiraQuest approved a plan (the "Plan") to partially reverse the Stock
Purchase Agreement closed on September 29, 2000. The Plan includes; (i) the
Company's redemption of all its outstanding preferred shares; (ii) the return by
MediQuik to MiraQuest of all its membership units; (iii) the restructuring of
the Ball loan to an equity position; (iv) an additional cash equity contribution
of $500,000 from MiraQuest to the Company; (v) MiraQuest's agreement to sell
back for a nominal amount a number of shares of the Company's common stock
necessary to reduce MiraQuest's equity ownership to approximately 30% once a new
capital partner is found for the Company; and (vi) MiraQuest's agreement to
relinquish its nominal control of the Company's Board of Directors at the next
annual shareholders meeting. On April 23, 2001, the Committee proposed a formula
for a partial reversal of the transaction (the "Plan"), and a quorum of the
Board of Managers of MiraQuest Ventures, LLC, ratified, approved, and adopted
the plan. On the same day, a quorum of the Board of Directors of MediQuik
Services, Inc. also ratified, approved, and adopted the Plan. In general, the
Plan calls for an additional investment by MiraQuest of $500,000, conversion of
the Ball Note to an equity investment, exchange of the MiraQuest units owned by
MediQuik for all of the MediQuik Preferred Stock and part of the MediQuik common
stock held by MiraQuest, and surrender of MiraQuest's control of the MediQuik
Board of Directors later in 2001. Further equity investments, mergers or
acquisitions, or debt secured by us would result in


                                       10
<PAGE>

the reduction of MiraQuest's ownership to below 30%. The Plan is expected to be
finalized by June 30, 2001. As of June 6, 2001, the Company had received
$490,000 of the $500,000 equity contribution by MiraQuest contemplated by the
Plan.

      Accounts receivable are primarily derived from payments due to us by
managed care plans, insurance companies, and government programs. As revenues
increase, we expect working capital requirements to increase. Standard medical
billing cycles for managed care plans average between 45-60 days. We expect to
experience similar billing cycles as direct managed care plan business
increases.

      In December 1999, we began raising money from investors through a private
offering of securities at a price of $2.00 per unit, which included one share of
MediQuik common stock and two warrants to purchase a share of common stock
exercisable at $2.00 per share. We raised a total of $532,500 through the
offering's expiration in August of 2000.

      On January 24, 2001, the Company obtained a loan from Ball Investors, LLC
("Ball"), which is a related party to MiraQuest. The loan has a principle amount
of $500,000, and requires quarterly interest payments, with a term of 24 months,
and included a requirement that Ball be given two seats on the MediQuik Board as
well as warrants to purchase MediQuik shares and conversion rights, thus giving
MiraQuest and its affiliates the ability to appoint 6 of the eleven members of
the Board. See Note 2 (Investments/Equity Transactions) to the financial
statements for a discussion of the MiraQuest transaction and the proposed
restructuring, including the Ball Note.

Results of Operations

      We are expanding through internal sales growth and we plan to conduct
strategic acquisitions to further fuel growth and accelerate the time to market
of additional planned services. During 1998 and 1999, we established: (i)
corporate marketing and fulfillment operations; (ii) contractual relationships
with product manufacturers; (iii) contractual relationships with specialty
service providers; (iv) contractual relationships with insurance payors and
provider networks; (v) contractual relationship with a pharmacy products
distribution company; and (vi) initial patient enrollment and fulfillment
operations. During 1999, we expanded our sales efforts, signing 6 new diabetes
management contracts. In 2000, we continued our development of these programs,
and began to offer pharmacy fulfillment as an adjunct service to medical supply
fulfillment. In October 2000, we conducted a test marketing campaign using mass
media, and are evaluating the results. In April of 2001, we implemented our
information technology platform to track all aspects of our customer service
function, from ordering to fulfillment to tracking of surveys, results, and
scheduling of other services.

Revenue from Operations

      Total revenue of $614,983 for the quarter ended March 31, 2001 grew by 91%
from $321,929 for the same quarter of 2000. Revenue growth was derived from


                                       11
<PAGE>

diagnostic, supply, and pharmaceutical sales to managed care plans, providers
and patients. We are currently deriving the majority of our revenues through
direct sales to managed care plans. We expect to realize improvement in gross
margin percentages with increased direct managed care plan revenues which
include disease management services. Cash flow from operations has not been
sufficient to fund all our operating activities to date.

      MediQuik has received patients primarily through agreements with managed
care plans and provider networks. Although management believes that patient
referrals generated through the managed care plans should increase, we intend to
pursue direct marketing and government programs to increase our sales in the
future. We cannot assure you that such efforts will result in increased patient
sales.

Gross Profit

      Gross profit was $180,333 or 29% of revenue, for the 3 months ended March
31, 2001, representing a gross profit increase of 307%. Gross profit was derived
from diagnostic product sales to managed care payors and patients, as well as
pharmaceutical sales and disease management tools . While the medical supply
gross profit percentage is the result of volume purchase discounts, and the
disease management tools' gross profit margin is high as a function of volume
versus development costs, the pharmaceutical gross profit percentage is much
smaller due to outsourcing fulfillment to a licensed provider. We expect
increases in overall gross profit percentage in the future with increased
disease management tools sales to managed care plans, medical supply volume
purchasing increases, and increased sales of non-medical, higher margin products
to our customer base offsetting the lower-margin pharmaceutical sales, although
we cannot assure you that our overall gross profit percentage will so increase.

Operating Expenses/Loss From Operations/Net Loss

      Operating expenses of $674,656 for the 3 months ended March 31, 2001,
increased by 20% over the comparable period in 2000. The loss from operations
for the quarter decreased by 5% from $522,287 to $495,860, attributable to the
increased gross profit percentage and the operating expense decrease. The net
loss also declined by 5% for the comparable period. We expect the net loss to
decrease with increased revenues and gross profits from business operations, and
with the restructuring of the MiraQuest transaction under the plan adopted by
the Boards of Directors of both companies (see "Liquidity and Capital
Resources"), although we cannot assure you that this will be the case.
ChronicRX.com had a no activity for the quarter, and had a deficiency in net
assets.

                                   * * * * * *


                                       12
<PAGE>

                          PART II. - OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

      A.    Exhibits

            Exhibit No.        Description of Exhibit
            -----------        ----------------------

            *(b)(3)(i)         Certificate of Incorporation of MediQuik

            *(b)(3)(ii)        Bylaws of MediQuik

            *(b)(16)           Letter On Change in Certifying Accountant

            *Previously filed with the Commission

      B.    Reports on Form 8-K

      A current report on Form 8-K was filed with the Securities and Exchange
Commission on June 1, 2001, reporting that MediQuik terminated Deloitte &
Touche, LLP and retained Malone & Bailey, PLLC as its independent accountants.
The Form 8-K was amended on Form 8-K/A to include Deloitte & Touche's Letter On
Change in Certifying Accountant and filed with the Securities and Exchange
Commission on June 15, 2001.

                                    PART III.

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date: June 15, 2001                     MediQuik Services, Inc.


                                        By: /s/ Robert Teague
                                        ----------------------------------------
                                        Robert Teague,
                                        Chief Executive Officer and Chairman of
                                        the Board


                                       13